-
1دورية أكاديمية
المؤلفون: Anna Miriam John (11927607), Harsimranjit Sekhon (11851883), Jeung-Hoi Ha (1998886), Stewart N. Loh (1332594)
مصطلحات موضوعية: Biophysics, Biochemistry, Cell Biology, Genetics, Molecular Biology, Neuroscience, Biotechnology, Immunology, Developmental Biology, Cancer, Physical Sciences not elsewhere classified, specifying yellow fluorescence, full genetic encodability, energy barriers present, closure entropy principle, also likely responsible, intramolecular exchange reaction, specifying green fluorescence, optical readout ), induced chromophore maturation, folds upon binding, input domain drives, input domain consists, couple ligand binding, gfp surface loop, gfp color shift, strand exchange mechanism, cpfkbp folding induces, input domain, strand exchange
-
2دورية أكاديمية
المؤلفون: Nicholas A. Jose (11553519), Jithin John Varghese (6095030), Samir H. Mushrif (1559155), Hua Chun Zeng (1441510), Alexei A. Lapkin (484904)
مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Microbiology, Ecology, Space Science, Environmental Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, tunable chemical composition, different mof surfaces, functionally diverse surfaces, different solvent environments, diverse range, via <, unique opportunity, synthesized using, situ <, oriented attachment, membrane separation, likely responsible, high anisotropy, great potential, generation materials, electrochemical catalysis, controllable synthesis, building blocks, binding energy, applications , aggregation dynamics, 2d mofs
-
3دورية أكاديمية
المؤلفون: Volta U, Caio G, Tovoli F, De Giorgio R
المساهمون: Volta, U, Caio, G, Tovoli, F, De Giorgio, R
مصطلحات موضوعية: Non-celiac gluten sensitivity is still an undefined syndrome with several unsettled issues despite the increasing awareness of its existence. Gluten is likely responsible for the clinical picture in a subset of patients, whereas in other cases it concurs to this syndrome together with fermentable mono-oligo-disaccharides and polyols and wheat proteins (e.g., amylase trypsin inhibitors). Innate immunity plays a pivotal role in the development of this syndrome, which is characterized by gut inflammation without villous atrophy and likely changes of intestinal barrier function. Data on its epidemiology are still undefined and largely variable. In the USA its prevalence varies from 0.6% to 6% in primary or tertiary care, respectively. Clinically, patients complain of gastrointestinal and extra-intestinal symptoms triggered by the ingestion of gluten without evidence of celiac disease and wheat allergy. Intestinal symptoms resemble those of irritable bowel syndrome, whereas neurological signs are quite common among extra-intestinal manifestations. So far, there are no biomarkers for non-celiac gluten sensitivity, but about half of patients shows anti-gliadin antibodies of IgG class. Although not specific for non-celiac gluten sensitivity, the detection of such antibodies can support the diagnosis in patients with gluten-related symptoms. In the absence of diagnostic biomarkers a double-blind, placebo-controlled food challenge is currently the best way for confirming non-celiac gluten sensitivity. Studies aimed at clarifying the pathophysiological, clinical and laboratory features of non-celiac gluten sensitivity will help a better management of patients with this novel and intriguing clinical entity.
وصف الملف: STAMPA
العلاقة: volume:8; issue:4; firstpage:225; lastpage:231; numberofpages:7; journal:ITALIAN JOURNAL OF MEDICINE; http://hdl.handle.net/11392/2407873Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84919427929
-
4
المؤلفون: Umberto Volta, Francesco Tovoli, Giacomo Caio, Roberto De Giorgio
المساهمون: Volta U., Caio G., Tovoli F., De Giorgio R.
المصدر: Italian Journal of Medicine, Vol 8, Iss 4, Pp 225-231 (2013)
مصطلحات موضوعية: medicine.medical_specialty, Non-celiac gluten sensitivity is still an undefined syndrome with several unsettled issues despite the increasing awareness of its existence. Gluten is likely responsible for the clinical picture in a subset of patients, whereas in other cases it concurs to this syndrome together with fermentable mono-oligo-disaccharides and polyols and wheat proteins (e.g., amylase trypsin inhibitors). Innate immunity plays a pivotal role in the development of this syndrome, which is characterized by gut inflammation without villous atrophy and likely changes of intestinal barrier function. Data on its epidemiology are still undefined and largely variable. In the USA its prevalence varies from 0.6% to 6% in primary or tertiary care, respectively. Clinically, patients complain of gastrointestinal and extra-intestinal symptoms triggered by the ingestion of gluten without evidence of celiac disease and wheat allergy. Intestinal symptoms resemble those of irritable bowel syndrome, whereas neurological signs are quite common among extra-intestinal manifestations. So far, there are no biomarkers for non-celiac gluten sensitivity, but about half of patients shows anti-gliadin antibodies of IgG class. Although not specific for non-celiac gluten sensitivity, the detection of such antibodies can support the diagnosis in patients with gluten-related symptoms. In the absence of diagnostic biomarkers a double-blind, placebo-controlled food challenge is currently the best way for confirming non-celiac gluten sensitivity. Studies aimed at clarifying the pathophysiological, clinical and laboratory features of non-celiac gluten sensitivity will help a better management of patients with this novel and intriguing clinical entity, there are no biomarkers for non-celiac gluten sensitivity, Non-celiac gluten sensitivity, non-celiac gluten sensitivity, innate immunity, epithelial barrier function, amylase trypsin inhibitors, fermentable oligo-, di-, and monosaccharides, and polyols, anti gliadin antibodies, lcsh:Medicine, And polyol, which is characterized by gut inflammation without villous atrophy and likely changes of intestinal barrier function. Data on its epidemiology are still undefined and largely variable. In the USA its prevalence varies from 0.6% to 6% in primary or tertiary care, patients complain of gastrointestinal and extra-intestinal symptoms triggered by the ingestion of gluten without evidence of celiac disease and wheat allergy. Intestinal symptoms resemble those of irritable bowel syndrome, Disease, whereas in other cases it concurs to this syndrome together with fermentable mono-oligo-disaccharides and polyols and wheat proteins (e.g, Immunoglobulin G, NO, whereas neurological signs are quite common among extra-intestinal manifestations. So far, Anti gliadin antibodie, Non-celiac gluten sensitivity is still an undefined syndrome with several unsettled issues despite the increasing awareness of its existence. Gluten is likely responsible for the clinical picture in a subset of patients, but about half of patients shows anti-gliadin antibodies of IgG class. Although not specific for non-celiac gluten sensitivity, Epidemiology, medicine, placebo-controlled food challenge is currently the best way for confirming non-celiac gluten sensitivity. Studies aimed at clarifying the pathophysiological, Di, Irritable bowel syndrome, respectively. Clinically, Innate immunity, chemistry.chemical_classification, And monosaccharide, amylase trypsin inhibitors). Innate immunity plays a pivotal role in the development of this syndrome, biology, business.industry, the detection of such antibodies can support the diagnosis in patients with gluten-related symptoms. In the absence of diagnostic biomarkers a double-blind, Amylase trypsin inhibitor, lcsh:R, Epithelial barrier function, Fermentable oligo, nutritional and metabolic diseases, General Medicine, medicine.disease, Gluten, digestive system diseases, Pathophysiology, chemistry, clinical and laboratory features of non-celiac gluten sensitivity will help a better management of patients with this novel and intriguing clinical entity, Immunology, Anti-gliadin antibodies, biology.protein, business, Wheat allergy
وصف الملف: ELETTRONICO
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cc85ef7bda667c3a57e026843df3784Test
https://doi.org/10.4081/itjm.2013.461Test -
5دورية أكاديمية
المؤلفون: Hirschel, B., Francioli, P.
المصدر: New England Journal of Medicine, vol. 338, no. 13, pp. 906-8
مصطلحات موضوعية: Acquired Immunodeficiency Syndrome/drug therapy/mortality Anti-HIV Agents/economics/*therapeutic use Drug Costs HIV Infections/*drug therapy HIV Protease Inhibitors/therapeutic use Humans United States/epidemiology and North America is most likely responsible for the observed marked declines in AIDS-related morbidity and mortality in 1995 and 1996, while the addition of protease inhibitors resulted in further benefit in late 1996 and 1997. The number of inpatients with AIDS has decreased while the number of outpatients has increased, reflecting major improvements in the treatment of HIV infection. However, simpler treatments are needed and much remains to be learned about how to safely apply these new biomedical tools against HIV/AIDS, including the nature of therapy-related long-term complications. Furthermore, funds are still needed for ongoing research and prevention. For the average AIDS patient in developing countries, highly active antiretroviral therapy is an inaccessible dream, and merely a diversion for developing country health ministries from more pressing concerns which threatens more cost-effective programs against HIV, such as the targeted distribution of condoms or the treatment of sexually transmitted diseases which facilitate the spread of HIV. Since nothing will likely bridge this gap between poor and rich countries, only prevention and a vaccine will likely make a real difference for the poor in the battle against HIV/AIDS.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/9516228; info:eu-repo/semantics/altIdentifier/pissn/0028-4793; https://serval.unil.ch/notice/serval:BIB_05F581F18561Test
الإتاحة: https://doi.org/10.1056/NEJM199803263381310Test
https://serval.unil.ch/notice/serval:BIB_05F581F18561Test
